Omeros (OMER) reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback